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LOCAL CHEMICAL MEDIATORS 
Cell-to-cell communication is the key to most processes in the body, and this cell-to-cell 
communication uses chemical mediators.  Chemical mediators are classified into four groups: 
nervous, endocrine, paracrine, and autocrine (Table 10.1). 
 
Table 10.1 Chemical mediators (modified from Table 29.1 in Bullock S et al) 
 
Nerves secrete neurotransmitters that act over a short range, and have a relatively rapid 
action.  The neurotransmitters in the peripheral nervous systems have already been discussed  
and drugs and the central nerve system will be discussed in future chapters.  Endocrine glands 
secrete hormones into the blood, where they circulate until they find their target receptor.  
The actions of hormones are relatively prolonged.  Various hormones are discussed further in 
Systematic pharmacology.  The other groups of chemical mediators, paracrine and autocrine 
secretion, are involved in local actions.  Paracrine secretions are of local hormones released 
into the circulation to have an effect on a neighbouring cell.  These actions are relatively 
rapid.  The local hormones to be discussed are the prostaglandins, nitric oxide and endothelin.  
Actually, some of the actions of the prostaglandins are autocrine, whereby the action is on the 
secreting cell.  Histamine, 5-hydroxytryptamine (5-HT) and cytokines also have some 
autocrine activity.  As there is overlap between the paracrine and autocrine actions of some 
chemical mediators, I prefer just to call the combination of local hormones and autocoids, 
local chemical mediators.  In the following sections, some important local chemical 
mediators are discussed, and how drugs can modify the effects of these chemical mediators 
are considered. 
 
10.1 Histamine and Cytokines 
 
The highest concentrations of histamine in the body are stored in mast cells, a cell found in 
connective tissue that contains granules of chemicals including histamine.  In the periphery, 
histamine is an autocoid.  The two best characterised effects of histamine are its major roles 
in allergy and in gastric secretion. Histamine is stored in secretory granules in mast cells, and 
basophils (circulating equivalent of mast cells).  The highest levels of histamine are found in 
lungs, followed by the mucous membranes, skin, stomach, and central nervous system.  
Histamine is released from mast cells and basophils in tissue damage or in hypersensitivity 
reactions.  Histamine H1- receptors mediate hypersensitivity, while histamine H2- receptors 
mediate gastric acid secretion.   
 
 10.1.2 Actions of histamine 
Histamine has a major role in Type 1 allergic reaction, which is the most common type of 
allergic reaction.  Type 1 allergy can lead to anaphylactic reactions.  Type I allergy is also 
known as immediate hypersensitivity reaction, and is often just called allergy.  Allergy can be 
caused by a number of things including grass pollen, house dust mites, certain foods, animal 
fur….  Medicines that can cause allergy include aspirin, angiotensin converting enzyme 
inhibitors, and penicillin.  With allergy, there is the release of contents of the mast cells and 
basophils.  The contents of mast cells include histamine, eicosanoids, and cytokines.  There 
local chemical mediators cause vasodilation, oedema, and inflammation.  Sometimes allergy 
is limited to certain sites e.g. food allergies affect gastrointestinal tract.  Whereas contact 
allergies may be limited to skin, where allergy is manifest as urticaria (hives) and atopic 
dermatitis (itching + raised red rash).  Allergy to inhalants e.g. grass pollen, may be limited to 
the respiratory system and manifest as rhinitis and asthma.  Mild allergic conditions may be 
treated with antihistamines.  Antihistamines are not effective in severe allergic reactions e.g. 
anaphylaxis, as mediators other than histamine are also involved. 
 
On the lung the hypersensitivity reaction of histamine is a H1-receptor-mediated 
bronchoconstriction.  On the nasal mucous membranes/skin, the hypersensitivity reaction is a 
H1-receptor-mediated dilation of terminal arterioles, which leads to the accumulation of red 
blood cells and produces the redness associated with allergy.  In the severe hypersensitivity 
reaction anaphylaxis, histamine H1-receptor mediated dilation causes a major decrease in 
blood pressure (hypotension).  The H1-receptor-mediated contraction of the endothelial cells 
of capillaries increases the space between the cells, allowing the contents of the capillaries 
(fluids, proteins) to flow into extracellular space to cause oedema (hives) (Figure 10.1). 
 
Figure 10.1 Oedema with histamine (Copyright QUT, Sheila Doggrell) 
 
The other major effect of histamine in the periphery is a H2-receptor mediated increase in 
gastric secretion.  Histamine is released, possibly from the enterochromaffin cells in the gut, 
and acts at H2-receptors on the parietal cells.  Stimulation of the H2-receptors leads to 
activation of adenylate cyclase, which in turn activated the H+/K+ ATP-ase, the proton pump.  
The proton pump, pumps H+ into the stomach to cause the acid environment. 
 
 
10.1.3 Drugs that modify the actions of histamine 
Theoretically, the effects of histamine (and any other chemical mediator) can be modified at 
every level of the system; i.e. at the level of synthesis, release, receptors, cell signaling and 
breakdown (Figure 10.2). 
   
 
Figure 10.2 How drugs can modify the actions of local mediators (Copyright QUT, Sheila 
Doggrell) 
 
With histamine we have important drugs that modify at the level of release and receptors.  
The release of histamine and leukotrienes from mast cells is inhibited by cromoglycate, 
which is occasionally used in the maintenance treatment of asthma.  Cromoglycate is only 
effective if the histamine and leukotrienes are still in the mast cells.  After the histamine 
and/or leukotrienes have been released, it is too late for cromoglycate to have an effect.  
 
Another level at which the effects of histamine is at the receptors.  Antagonists at H1-
receptors are commonly used in the treatment of allergic rhinitis, conjunctivitis (allergy of 
the eye), and chronic urticaria (skin allergy).  The first generation (older) H1-receptor 
antagonists crossed the blood brain barrier and caused sedation. Examples of first generation 
H1-receptor antagonists include dexchlorpheniramine and diphenyhydramine. 
Dexchlorpheniramine is still used in the treatment of allergic rhinitis, and chronic urticaria, 
whereas diphenyhydramine is no longer used for hypersensitivity reactions, but is used as a 
mild sedative in insomnia.  The second generation H1-receptor antagonists are less able to 
cross the blood brain barrier and cause less sedation.  An example of a second generation H1-
receptor antagonists is fexofenadine. Fexofenadine is used in the treatment of allergic rhinitis 
and chronic urticarial. 
 
Antagonists at H2-receptors revolutionized the treatment of peptic acidity conditions such 
as peptic ulcer disease, gastro-oesphogus reflux disease (GORD), and dyspepsia, as there had 
been no good treatments previously.  An example of an H2-receptor antagonist is ranitidine 
(Ranitic).  Ranitidine is a relatively safe drug and is available over-the-counter (OTC) 
without a prescription in low doses.   
 
As histamine acting at the H2-receptor is only one of the stimulants of acid secretion, H2-
receptor antagonists are only effective against the histamine component.  There are other 
stimulants of gastric secretion such as gastrin and acetylcholine, and H2-receptor antagonists 
do not inhibit this stimulation of acid secretion whereas proton pump inhibitors do.  Thus 
proton pump inhibitors are often preferred to the H2-receptor antagonists in peptic acidity 
conditions, as they are more effective. 
 
 10.1.4 Cytokines 
In addition to allergy, cytokines have a role in inflammatory conditions, especially in 
autoimmune-inflammatory conditions such as rheumatoid arthritis.  Cytokines are small 
secreted proteins that mediate and regulate inflammation, immunity, and haematopoiesis.  
Cytokines generally act over short distances, short time spans, and at very low 
concentrations.  They act to alter gene expression.   
 
Interleukins (IL) are cytokines made by one leukocyte and acting on other leukocytes.  
There are many interleukins, but IL-1 is the main one associated with inflammation.  IL-1 
stimulates T-lymphocytes to produce IL-2, which promotes inflammation, and causes fever.  
IL-2 stimulates growth and activation of other T cells and NK (natural killer) cells.   
 
Tumour necrosis factor (TNF) is the other cytokine that has a prominent role in 
inflammation.  TNF kills tumour cells, and hence the name.  TNF stimulates the activities of 
T cells and eosinophils, which are cells involved in the inflammatory process. 
 
The interleukin, IL-1, is the main one associated with inflammation.  IL-1 stimulates T-
lymphocytes to produce IL-2, which promotes inflammation, and causes fever. IL-2 
stimulates growth and activation of other T cells and NK (Natural Killer) cells (inflammation 
and immunity) (Figure 10.3).  
 
Anakinra is an IL-1 antagonist used in the severe inflammation associated with rheumatoid 
arthritis.  It is administered subcutaneously.  By acting as an antagonist at IL-1 receptors, 
anakinra in turn inhibits the production of IL-2 from T-lymphocytes (Figure 10.3).  Anakinra 
commonly causes allergy, and treatment has the possibility of allowing serious infection, as 
the interleukins also have a major role in immunity. 
 
 
 
 
Figure 10.3 Mechanism of Anakinra 
 
Tumour necrosis factor (TNF) is the other cytokine that has a prominent role in 
inflammation.  Infliximab is an antibody to TNF.   Infliximab is administered intravenously, 
every 8 weeks in the hospital setting. During treatment with infliximab, bacterial infection is 
infrequent.  Infliximab is used in the treatment of rheumatoid arthritis and ankylosing 
spondylitis (degenerative inflammatory arthritis affecting the spine and sacroiliac joints). 
 
10.2 Eicosanoids  
Eicosanoids are also known as the arachidonic acid derivatives.  There are 3 types of 
eicosanoids; prostaglandins (PGs), thromboxanes (TXs), and Leukotrienes (LTs).  The 
eicosanoids are local hormones, which means they have effects close to where they are 
produced. 
 
 10.2.1 Cyclooxygenase (COX) and lipooxygenase system 
Arachidonic acid is acquired either as part of meat or from dietary linoleic acid (Figure 10.4).  
Normally, there is little free arachidonic acid, as it is readily incorporated into the 
phospholipids of the cell membrane. 
 
Figure 10.4 Cyclooxygenase and lipooxygenase pathways (Copyright QUT, Sheila Doggrell) 
 
The release of arachidonic acid from the phospholipids of the cell membranes requires the 
activation of the enzyme phopholipase A2.  Phospholipase A2 is activated by a whole range 
of physical, chemical, hormonal, neuronal and immunological stimuli.  Once released, 
arachidonic acid is readily metabolised.  In the areas where the enzyme cyclooxygenase is 
present, arachidonic acid is metabolised to prostaglandins and thromboxanes.  In the areas 
where the enzyme lipooxygenase is present, arachidonic acid is metabolised to leukotrienes 
(Figure 10.4).   
 
The eicosanoids produced from the cyclooxygenase pathways are prostaglandins (PGs), 
including PGI2 (which is also known as prostacyclin), and thromboxane A2 (TXA2).  The 
eicosanoids produced from the lipooxygenase pathways are known as leukotrienes (LTs).  
The effects of all the eicosanoids are local and receptor mediated.  The actions of the 
eicosanoids are short, as they are rapid metabolised (inactivated) and there are no prolonged 
effects due to recirculation.  PGD2 acts at DP receptors, PGE2 acts at EP receptors (which 
have been further divided into EP1 and EP2), PGF2α acts at FP receptors, PGI2 acts at IP 
receptors, and TXA2 acts at TP receptors.  The products of the lipooxygenase pathway, the 
LTs, act at LT receptors. 
 
10.2.2 Actions of eicosanoids 
The eicosanoids have many, many actions.  The actions discussed here are those that we 
modify with medicines.   
 
Eicosanoids from both the cyclooxygenase and lipooxygenase pathways have a major role in 
inflammation.  With a variety of physical, chemical, bacterial, and immunological stimuli, 
phospholipase A2 is activated, and the cyclooxygenase pathway is activated to produced 
prostaglandins, and the lipooxygenase pathway to produced leukotrienes, and this 
combination leads to inflammation (Figure 10.5). 
 
Figure 10.5 Eicosanoids and inflammation (Copyright QUT, Sheila Doggrell) 
 
There are 3 components to inflammation; pain, erythema (redness) and oedema (swelling).  
The pain is partly due to prostaglandins E2 and I2 which sensitive afferent nerve endings (the 
sensory nervous system), and this causes an amplification of pain.  The erythema is due to 
both leukotrienes and prostaglandins, with the redness being due to vasodilation and 
congestion of blood vessels, with localised high concentrations of red blood cells.  The 
oedema is due to the leukotrienes increasing vascular permeability, and causing proteins to 
leave blood vessels in much the same way as histamine causes oedema (Figure 10.5).  To 
overcome eicosanoids-induced inflammation, drugs must inhibit both the cyclooxygenase and 
lipooxygenase pathways. 
 
The other actions of eicosanoids discussed here are those of the cyclooxygenase pathway 
only.  Firstly, PGE2 has a major role in fever.  Fever is associated with disease states, 
infections, tissue damage, and malignancy.  Fever involves increased PGE2 synthesis in 
hypothalamus, and PGE2 increases set point of body temperature to give the fever.  In some 
situations this can be useful, e.g. increased body temperature probably helps fight bacterial 
infections by killing the bacteria.  However, excessive increases in temperature are harmful to 
a body designed to act at 370C.  To reduce fever, drugs need only inhibit the cyclooxygenase 
pathway. 
 
Secondly, the products of the cyclooxygenase pathway have important roles on the 
cardiovascular system.  PGs cause vasodilation of most vascular beds. An important role for 
PGE2 and PGI2 is to keep a specialised blood vessel, the ductus arteriosus (lung bypass), open 
prior to birth.  Often the effects of PGI2 and TXA2 oppose each other, thus whereas PGI2 
causes vasodilation, TXA2 causes vasoconstriction of most vascular beds.   
 
Platelets are a form of blood cells produced in the bone marrow.  Platelet aggregation is the 
first step in coagulation, and PGI2 prevents platelet aggregation, whereas TXA2 increases 
platelet aggregation.  The PGI2 is produced by the activity of the COX in the endothelial cells 
that line the inside of the blood vessels.  PGI2 activates the IP receptors on the platelet cells to 
increase the activity of adenylate cyclase and levels of cAMP, which prevents platelet 
aggregation (Figure 10.6). 
 
Figure 10.6 Prostacyclin and platelet aggregation (Copyright QUT, Sheila Doggrell) 
 
Thromboxanes do the opposite to prostacyclin i.e. TXA2 causes platelet aggregation.  When 
there is damage to a blood vessel, the area is no longer protected by endothelium released 
PGI2, and the platelets stick to collagen.  Once activated platelets produce TXA2, which 
initiates more platelet aggregation, by having the opposite effect on the platelet to 
prostacyclin.  Thus, TXA2 inhibits adenylate cyclase, to decrease levels of cAMP, and 
increase platelet aggregation.   
 
Platelet aggregation has an important role in blood vessel repair.  When the blood vessel is 
damaged, platelet aggregation is the first step in blood vessel repair, which takes place under 
the protection of the clot.  Unfortunately, excessive platelet aggregation is quite common, and 
can be part of several cardiovascular conditions.  Excessive platelet-platelet aggregation can 
partially block the blood vessel.  Blood flow can then dislodge the clump of platelets and they 
can move downstream to block a smaller vessel, the blockage is known as a thrombus, and 
the condition is thrombosis.  Coronary thrombosis underlies myocardial infarction (heart 
attacks).  Thus, it is important to avoid excessive platelet aggregation, which can be done by 
decreasing the levels of TXA2. 
 
Thirdly, prostaglandins are cytoprotective in the stomach.   
 
Figure 10.7 Prostaglandins and acid production (Copyright QUT, Sheila Doggrell) 
 
PGE2 and PGI2 give protection from the damaging effects of acid in the stomach.  Thus, acid 
secretion induced by histamine, gastrin and food is countered by PGE2 and PGI2, which 
inhibit the acid secretion (Figure 10.7).  In addition to inhibiting acid secretion, PGE2 and 
PGI2 stimulate the production of mucus, which protects cells from acid. 
 
Finally, PGE2 and PGF2α, with the hormone oxytocin, contract the uterus to initiate labour 
and childbirth.  If these PGs are produced too early, labour occurs prematurely leading to 
preterm birth. 
 
The leukotrienes, produced by the lipooxygenase pathway, have a major role in immediate 
type hypersensitivity.  Thus, after an antigen-antibody reaction, mast cells release histamine 
and leukotrienes.  Histamine causes a histamine H1-receptor mediated bronchoconstriction, 
but this is minor compared to the effects of leukotrienes.  As the histamine H1-receptor 
antagonists are only effective against histamine, not leukotrienes, this explains why histamine 
H1-receptor antagonists are not effective in severe hypersensitivity, where leukotrienes are 
the major players.  The leukotrienes LTC4, LTD4 and LTE4 are potent bronchoconstrictors, 
which can lead to bronchospasm, and LTB4 is a chemotractant for neutrophils and 
eosinophils, which are cells prominent in inflammation.  The leukotrienes also stimulate 
mucous production. 
 
 10.2.3 Drugs that modify the actions of eicosanoids 
There are a number of ways that medicines are used to modify the actions of eicosanoids.  
Firstly, at the level of synthesis, the production of all the eicosanoids can be inhibited by 
inhibiting phospholipase A2 with the glucocorticoids.  Also, at the level of synthesis, the 
production of prostaglandins and thromboxanes, but not leukotrienes, can be inhibited by 
inhibiting COX.  There are two forms of COX, and both forms are inhibited by non-selective 
COX inhibitors such as aspirin, paracetamol, ibuprofen, and piroxicam.  COX-2 is selectively 
inhibited by celecoxib and diclofenac.  Secondly, the actions of the eicosanoids can be 
modified at the levels of the receptors.  Selective agonists are available for the EP receptors 
(misoprostol and dinoprostone), IP receptor (iloprost) and FP receptor (latanoprost).  These 
medicines are now discussed systematically. 
 
 
  10.2.3.1 Inhibit phospholipase A2 
The glucocorticoids inhibit phospholipase A2 to reduce the activity of both cyclooxygenase 
and lipooxygenase, and decrease the levels of prostaglandins, thromboxanes, and 
leukotrienes.  Prostaglandins and leukotrienes are important, but not the only mediators of 
inflammation.  The glucocorticoids are potent anti-inflammatory agents and this is partly due 
to decreasing the levels of prostaglandins and leukotrienes, but this is not the only 
inflammatory mechanism of glucocorticoids. 
 
  10.2.3.2 Non-selective cyclooxygenase inhibitors 
Aspirin is a non-selective inhibitor of cyclooxygenase (COX), which leads to reduced 
production of prostaglandins, and thromboxanes, but not leukotrienes. There are a group of 
non-selective inhibitors of COX, which are known as the NON-STEROIDAL ANTI-
INFLAMMATORY DRUGS (NSAIDs), to distinguish them from the steroid anti-
inflammatory drugs (the glucocorticoids).  NSAIDs include aspirin, paracetamol, 
ibuprofen, and piroxicam.  The NSAIDs are probably the most commonly used drugs. 
 
Aspirin is an irreversible non-selective inhibitor of COX, whereas all the other NSAIDs are 
reversible inhibitors of COX.  Aspirin reverses the effects of the prostaglandins, to be a mild 
analgesic, anti-pyretic, and partially anti-inflammatory.  Aspirin is only partially anti-
inflammatory as it only prevents the inflammatory effects to prostaglandins, not those to 
leukotrienes or other inflammatory mediators.  A novel action of aspirin is that low dose it 
inhibits platelet aggregation to be an anti-coagulant, by preferentially blocking synthesis of 
TXA2.  This preferential action may be related to the irreversible nature of aspirin.  Low dose 
inhibits platelet aggregation by preferentially blocking synthesis of TXA2, and this will be 
discussed more fully in the section on Cardiovascular Therapeutics.  Aspirin is used to 
prevent myocardial infarction/thrombosis. 
 
The two main problems with aspirin are ulcers and hypersensitivity.  Thus, chronic users of 
aspirin for its antithrombotic effect or of the other NSAIDs for analgesia, have a 2-4% of 
developing an ulcer.  The ulcers are due to removal of the cytoprotective effects of 
prostaglandins in the stomach.   
 
The hypersensitivity to NSAIDs, which was first described for aspirin, is due to the inhibition 
of cyclooxygenase leading to a build-up of arachidonic acid, which is then metabolised by the 
lipooxygenase pathway to leukotrienes (Figure 10.8).  The extra leukotrienes may lead to 
asthma and angioedema. 
Figure 
10.8 NSAIDs and hypersensitivity (Copyright QUT, Sheila Doggrell) 
 
Leukotrienes are potent mediators of hypersensitivity reactions such as rhinitis, asthma, and 
angioedema.  Thus, the use of NSAIDs can be associated with hypersensitivity reactions, 
especially if people are susceptible.  For instance, 5-10% of asthmatics are sensitive to 
aspirin.  After a hypersensitivity reaction to aspirin or another NSAID, the NSAIDS should 
be avoided by that person. 
 
Paracetamol is an inhibitor of COX, and consequently reduces the levels of prostaglandins.  
Thus, paracetamol is effective as a mild analgesic, and as an antipyretic, and is usually 
preferred to aspirin for these indications, as it is milder on the stomach.  Paracetamol is NOT 
anti-inflammatory, possibly because some products of inflammation stop paracetamol from 
inhibiting COX.  Thus, paracetamol is not indicated for inflammation, and you need to use 
aspirin or other NSAIDs in the treatment of inflammation.  Paracetamol also has no effect on 
platelet aggregation or clotting, possibly because the effect of low dose aspirin to inhibit 
platelet aggregation and clotting may depend on aspirin being an irreversible inhibitor.  In 
contrast, paracetamol is a reversible inhibitor of COX and does not inhibit platelet 
aggregation.  The outcome of this is that you cannot substitute paracetamol for aspirin for 
cardioprotection, as it is not anti-thrombotic. 
 
Ibuprofen (Nurofen) is a non-selective COX inhibitor.  Ibuprofen can be used as an 
analgesic, an anti-pyretics and an anti-inflammatory agent in similar way as aspirin.  
Ibuprofen is effective in pain of low-to-moderate intensity, such as nonspecific relief of 
minor aches and pain (headache, arthritis, dysmenorrhea, neuralgia, myalgia).  Ibuprofen is 
also used in chronic conditions such as rheumatoid arthritis and osteoarthritis, where they are 
only partially effective as anti-inflammatory agents due to the mediators, other than 
prostaglandins, of inflammation.  Ibuprofen has a similar efficacy in these conditions as 
aspirin.  However, ibuprofen is generally preferred to aspirin as an analgesic, an anti-pyretics 
and an anti-inflammatory agent as it has greater tolerability than aspirin on chronic use i.e. 
less likely to cause ulcers.  However, ibuprofen has a lesser ability to inhibit platelet 
aggregation than aspirin, and is not suitable as agents to inhibit platelet aggregation e.g. in the 
secondary prevention of myocardial infarction or stroke. 
 
Piroxicam is a non-selective COX inhibitor, which is predominantly used as an anti-
inflammatory agent.  Independently of COX inhibition, piroxicam inhibits the activation of 
neutrophils.  Neutrophils accumulate in areas of injury or infection, and release inflammatory 
cytokines.  Thus, inhibiting the activation of neutrophils is another anti-inflammatory 
mechanism, and contributes, to the anti-inflammatory action of piroxicam (Figure 10.9).  
Thus, piroxicam has more anti-inflammatory activity that the agents that just inhibit COX.   
 
 
 
Figure 10.9 Mechanism of piroxicam 
Piroxicam, like the other NSAIDs discussed, is active after oral administration.  However, 
unlike the other NSAIDs discussed, piroxicam has a slow onset of action, and is slow to reach 
steady state (7-12 days), and has a t1/2 (half-life) of elimination is about 50 hours.  Because of 
the slow onset of action, piroxicam is not used in acute conditions (pain, fever), but is used in 
the long term treatment of chronic conditions such as rheumatoid arthritis and osteoarthritis. 
 
The major problem with non-selective NSAIDs is ulcers and gastrointestinal bleeding, 
especially with aspirin.  COX has too forms, COX-1 is constitutively expressed (always 
active e.g. stomach) whereas COX-2 is induced in response to stimuli.  NSAIDs inhibit 
COX-2 to reduce pain and inflammation, which are its beneficial effects, but NSAIDs also 
inhibit COX-1 to reduce levels of the cytoprotective prostaglandins, which is detrimental 
(Figure 10.10). 
 
 
Figure 10.10 NSAIDs and COX-1 and COX-2 (Copyright QUT, Sheila Doggrell) 
 
Thus, drugs that are selective COX-2 inhibitors should give still be able to reduce pain and 
inflammation, but cause less COX-1 inhibition and less bleeding.  This was the rationale for 
developing selective COX-2 inhibitors. 
 
  10.2.3.3 Selective COX-2 inhibitors 
Rofecoxib is the most selective COX-2 inhibitor marketed to date.  Clinical trials showed 
that rofecoxib was very effective against the pain and inflammation of chronic conditions 
such as osteoarthritis and rheumatoid arthritis. Rofecoxib was very popular with patients, 
many of whom considered rofecoxib a wonder drug, as it gave them more relieve from pain 
and inflammation than NSAIDs.  As predicted, from the COX-2 selectivity, there was less 
gastrointestinal toxicity with rofecoxib than with non-selective NSAIDs.  However, 
eventually, rofecoxib was withdrawn for causing a slight increase in cardiovascular toxicity, 
mainly myocardial infarction (heart attacks).  This was an unexpected finding, and the reason 
for it is still being worked out.   
 
Celecoxib (Celebrex) is not as COX-2 selective as rofecoxib.  Unfortunately, this meant that 
it celecoxib is still able to inhibit enough COX-1 to induce some gastrointestinal toxicity.  
Indeed, clinical trials have failed to establish less gastrointestinal toxicity with celecoxib than 
with the non-selective NSAIDs.  With regard to COX-2 inhibitory effects, cardiotoxicity is 
borderline and/or disputed with celecoxib.  Celecoxib has not been withdrawn, but comes 
with a warning not to be used in subjects with cardiovascular or cerebrovascular disease i.e. 
subjects with increased cardiovascular risk.  Celecoxib is active after oral administration, 
lipophilic and widely distributed, with a t1/2 of elimination of 11 hours.  Celecoxib is 
commonly used for the relief of inflammation in osteoarthritis and rheumatoid arthritis.  
Celecoxib is also used to give relief from post-extraction dental pain. 
 
Although it has been around for many years, only recently has diclofenac (Voltaren) been 
shown to be a selective inhibitor of COX-2.  Diclofenac has a similar selectivity for COX-2 
to celecoxib.  Thus, the gastrointestinal toxicity and cardiotoxicity of diclofenac is similar to 
that of celecoxib.  Diclofenac has rapid absorption, with a short t1/2 (1-2 hours).  It is effective 
as an analgesic, antipyretic, and anti-inflammatory agent.  Diclofenac is used long term in 
osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis (a form of arthritis that affects 
the spine).  Diclofenac is also used short term use in acute musculoskeletal pain, 
postoperative pain, and dysmenorrhoea.   
 
The quest for a selective COX-2 inhibitor is presently stalled, as although rofecoxib had less 
gastrointestinal toxicity than NSAIDs, it induced cardiotoxicity.  Celecoxib and diclofenac do 
not have the cardiotoxicity, but do not have acceptable levels of gastrointestinal tolerability.  
Another approach to prevent gastrointestinal toxicity is to use celecoxib and diclofenac with 
gastrointestinal protective medicines.  Diclofenac is available in combination with 
misoprostol.  Misoprostol stimulates EP receptors to provide gastric cytoprotection, as 
discussed in the next section.  The combination of diclofenac and misoprostol has decreased 
gastrointestinal toxicity, compared to diclofenac alone.  The proton pump inhibitors (PPIs) 
can also be used to give gastrointestinal protection.  Omeprazole is the prototype PPI. There 
are other –prazoles, which are all proton pump inhibitors e.g. esomeprazole.  In addition to 
being used alone in the treatment of peptic ulcer, gastric reflux etc, the PPIs are also used for 
the prevention and/or treatment of gastrointestinal adverse effects of NSAIDs. 
 
  10.2.3.4 Agonists at prostaglandin receptors 
A number of agonists, showing selectivity for one or other of the prostaglandin receptors, are 
used clinically.  Firstly, misoprostol is a selective EP1 receptor agonist.  Misoprostol was 
developed for use to provide gastric cytoprotection, and it does suppress gastric ulceration.  
Indeed, misoprostol is as effective as the H2-receptor antagonists at preventing gastric 
ulceration.  However, misoprostol alone is not commonly used to provide gastric 
cytoprotection, as the proton pump inhibitors are preferred, probably because they have a 
greater efficacy.  Misoprostol is used as a gastric cytoprotective with diclofenac, to prevent 
gastric ulceration with the diclofenac.  When misoprostol is used for gastric cytoprotection, it 
is contraindicated in pregnant women as is a powerful uterine stimulant, and may cause 
premature labour.  This was originally considered as a detrimental effect of misoprostol when 
it was being used as a gastroprotective agent.  However, this detrimental effect, lead to the 
clinical development of misoprostol for another use. 
 
One use for a uterine stimulant is to induce abortions.  However, the pharmaceutical 
companies have mainly steered clear of the abortion controversy.  Thus, the pharmaceutical 
company that developed misoprostol, as a cytoprotective agent, did not go on to develop 
misoprostol as a uterine stimulant.  This development was done by others, mainly University 
clinical academics, and represents the off-label development of misoprostol as a uterine 
stimulant.  When pregnancy is complicated by early death, misoprostol is used to remove the 
remnants.  Misoprostol is not used alone for abortion but misoprostol is used with the 
progesterone antagonist mifepristone for early abortion.  The main adverse effect, when 
using misoprostol as a uterine stimulant, is gastrointestinal (diarrhoea).  
 
Dinoprostone is a selective EP2 receptor agonist, which increases contractions of uterus.  
Dinoprostone also relaxes the cervix.  This combination of effects makes dinoprostone useful 
in the induction or augmentation (increasing) of labour, especially when the cervix is not 
dilating. 
 
Selective agonists are also available for the prostacyclin (PGI2) IP receptors.  Prostacyclin 
inhibits platelet aggregation and is a potent vasodilator.  PGI2 is not active after oral 
administration, and is rapidly broken down.  Thus to use prostacyclin clinically, a continuous 
infusion is required, and this is not always convenient.  Iloprost is a synthetic analog of PGI2, 
which stimulates the IP receptors with a longer half-life than PGI2.  Iloprost is used in the 
treatment of pulmonary hypertension, a condition in which the hypertension is limited to the 
pulmonary circulation.  Iloprost is delivered by nebuliser, which gives a high local pulmonary 
concentration of iloprost, which is localised to the pulmonary vessel to cause dilation of the 
pulmonary vessels only. 
 
The ciliary muscle of the eye has FP receptors.  Stimulation of these receptors increases the 
aqueous humour outflow from the eye.  Latanoprost is an ester analog of PGF2α, and 
selective agonist of FP receptors.  Latanoprost is used in the treatment of ocular 
hypertension (glaucoma).  When ocular pressure is high, the optic nerve can be damaged, 
which can lead to irreversible.  By promoting aqueous humour outflow from the eye, 
latanoprost reduces intraocular pressure.  
 
  10.2.3.5 Leukotriene receptor antagonists 
Montelukast is a leukotriene receptor antagonist that is used in the prevention of asthma.  
It antagonises the LTC4, LTD4, and LTE4 receptors to reduce bronchoconstriction and 
inflammation.  
 
 
10.3 5-Hydroxtryptamine (serotonin), nitric oxide, and endothelin 
The final 3 local chemical mediators to be discussed briefly, with respect to therapeutics, are 
5-hydroxytryptamine (5-HT, also known as serotonin), nitric oxide (NO), and endothelin.  5-
HT is a neurotransmitter and a local chemical.  5-HT1 receptor subtypes and 5-HT2 receptors 
are involved in migraine, whereas 5-HT3 and 5-HT4 receptors are involved in gastrointestinal 
motility. 
 
  10.3.1 5-HT and migraine 
Excessive cranial blood vessel dilation and inflammation underlies the pain of migraine.  
Ergotamine has gone from being a poison to therapy for migraine.  Ergot alkaloids are the 
product of a fungus that grows on corn.  In biblical times, when they ate contaminated corn, it 
caused plague.  The symptoms of the plaque were due to the ergot alkaloids causing intense 
vasoconstriction of the extremities leading to gangrene, and stimulation of the uterus causing 
abortion.  Ergotamine is one of the ergot alkaloids.  The actions of ergotamine include being 
a partial agonist at 5-HT1B/1D receptors.  Stimulation of the 5-HT1B/1D receptors on cranial 
blood vessels causes vasoconstriction. The vasoconstriction with ergotamine overcomes the 
excessive vasodilation of migraine. 
 
Sumitriptan is a 5-HT1B/1D agonists also used in the treatment of migraine attacks, and has 
two mechanisms, one of which is similar to ergotamine.  The central nervous system is 
involved in the excessive vasodilation of migraine.  Stimulation of 5-HT1B/1D receptors in the 
central nervous system may decrease the release of neurotransmitter onto the cranial blood 
vessels, and the excessive vasoconstriction (Figure 18.1).  Secondly, as with ergotamine, the 
triptans cause a direct stimulation of the 5-HT1B/1D receptors on the cranial blood vessels to 
cause vasoconstriction to overcome the excessive vasodilation. 
 
Figure 10.8 Mechanisms of triptans (Copyright QUT, Sheila Doggrell) 
 
In an attack of migraine, need a drug that acts quickly to relieve the attack.  When used 
orally, the bioavailability of sumitriptan is low (15%).  Also, after oral administration of 
sumitriptan, peak plasma concentrations are not reached for 1-2 hours, and onset of action 
may take up to 30 minutes, which is too slow for somebody who is having a migraine attack.  
Thus, we need a quicker effective route of administration for sumitriptan.  After 
subcutaneous or nasal spray administration of sumitriptan, the bioavailability is increased and 
the onset of action may occur in 15 minutes.   
 
Drugs used to prevent migraine attacks include the serotonin receptor antagonist 
(predominantly 5-HT2 receptor antagonist) e.g. pizotifen.  The action of pizotifen in 
preventing migraine is unknown.  However, it has been shown that two-thirds of patients, 
who regular suffer migraine attacks, have a 50% reduction in frequency of headache with 
pizotifen.  Unfortunately, pizotifen cause drowsiness, which makes it unpopular for continued 
use in patients. 
 
  10.3.2 5-HT and the gastrointestinal tract 
5-HT stimulates 5-HT3-receptors to increase vomiting.  The -etrons: e.g. ondansetron 
(prototype) are selective 5-HT3-receptor antagonists.  Ondansetron, and others in the -etron 
family are used to inhibition emesis.  The –etrons are the most effective agents for treating 
chemotherapy-induced nausea and vomiting. 
 
  10.3.3 Nitric oxide and angina 
Nitric oxide (NO) is a neurotransmitter and a local chemical mediator.  As a local chemical 
mediator, NO relaxes blood vessels.  There are a group of drugs that mimic NO by releasing 
NO, and the group is known as nitrovasodilators.  Examples of nitrovasodilators are 
nitroglycerin and isosorbide-5-mononitrate.  Nitrovasodilators release NO, which relaxes 
blood vessels, and is useful in the treatment and prevention of angina, which is due to 
diseased coronary arteries.  As diseased coronary arteries are difficult to dilate, 
nitrovasodilators have little effect on diseased coronary arteries.  Nitrovasodilators end an 
angina attack by causing venodilation, and reducing the workload on the heart, and this will 
be discussed further under Systematic Pharmacology. 
 
As discussed previously (eChapter 1), nitroglycerin undergoes extensive first pass liver 
metabolism, and cannot be used orally.  Rather, nitroglycerin is used as a sublingual tablet or 
spray (faster) in an attack of angina, and starts to work within a minute, but is only effective 
for a short time as has a t1/2 of about 3 minutes.  For a longer effect, and to prevent an anginal 
attack, nitroglycerin patches or ointment are used.  
 
Isosorbide-5-mononitrate is the only nitrate developed to date, that has no significant first 
pass liver metabolism, and can be used orally.  Isosorbide-5-mononitrate is used orally to 
prevent an angina attack.  
 
  10.3.4 Nitric oxide and erectile dysfunction 
On the smooth muscle of the corpus carvenosum (penile smooth muscle) endogenous nitric 
oxide both as a neurotransmitter and local chemical mediator stimulated guanylate cyclase to 
promote the conversion of GTP to cGMP.  The cGMP relaxes the corpus carvenosum to 
produce a penile erection.  The rapid breakdown of cGMP by phosphodiesterase V ends the 
relaxation and the erection.  Sildenafil inhibits phosphodiesterase V to increase and prolong 
the effects of cGMP, with increased relaxation of the corpus carvenosum and increased penile 
erection. 
10.3.5 Endothelin and pulmonary hypertension 
Endothelin is a peptide local hormone, and it is a potent vasoconstrictor. High levels of 
endothelin or an increased sensitivity in pulmonary circulation to endothelin occur in certain 
forms of pulmonary hypertension, high blood pressure limited to the pulmonary circulation.  
The effects of endothelin are receptor mediated, and bosentan is a non-selective endothelin 
receptor antagonist.  Bosentan is active after oral administration.  In pulmonary hypertension, 
bosentan reduces pulmonary pressure, and this leads to a reduction in the incidence of death, 
lung transplantation, and hospitalization for pulmonary hypertension. 
 
